Pilot study evaluates efficacy and safety of clascoterone cream and adapalene gel in acne patients, suggesting potential benefits for treatment.
Key Points
This study aims to evaluate the efficacy and safety of clascoterone cream 1% in combination with adapalene gel 0.3% in patients with acne.
20-week, open-label pilot study (NCT06336603) with patients aged ≥12 years with moderate-to-severe acne.
Patients applied clascoterone cream 1% twice daily and adapalene gel 0.3% once daily for 16 weeks with efficacy assessments conducted.
Tolerability and safety were evaluated through local skin reactions and adverse events over a 20-week period.
65% of patients achieved an Investigator's Global Assessment (IGA) score of clear (0) or almost clear (1) at week 16.
Significant reductions in inflammatory (90.5%), noninflammatory (84.8%), and total lesion counts (87.3%) at week 16 (all P<0.001).
The Dermatology Life Quality Index (DLQI) score showed a mean reduction of 3.7 (P=0.02) with treatment being well tolerated and no serious adverse events reported.